ANGN Angion Biomedica Corporation

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Elicio Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

28657F103

(CUSIP Number)

July 6, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Preliminary Note

This Amendment No. 1 (this “Amendment”) amends and restates in its entirety the Schedule 13G (the “Schedule 13G”) initially filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2022 by each of Vifor (International) Ltd., an entity formed under the laws of Switzerland (“Vifor (International)”), Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland (“VFMCRP”), and Vifor Pharma Ltd., an entity formed under the laws of Switzerland (“Vifor Pharma” and, together with Vifor (International) and VFMCRP, the “Reporting Persons”), relating to the shares of common stock, par value $0.01 per share (“Common Stock”), of Elicio Therapeutics, Inc. (formerly known as Angion Biomedica Corp.), a Delaware corporation (the “Issuer”).

As a result of the expiration on December 31, 2022 of the option granted to VFMCRP by Vifor (International), as of the date of this Amendment, VFMCRP no longer beneficially owns any Common Stock.

As a result of the merger of Vifor Pharma into Vifor Pharma Participations Ltd. pursuant to a merger agreement, dated May 11, 2023, as of the date of this Amendment, Vifor Pharma no longer beneficially owns any Common Stock.

On June 1, 2023, the Issuer completed a merger transaction, in connection with which, among other matters, the Issuer issued additional shares of Common Stock as merger consideration, effected a reverse stock split of the Common Stock at a ratio of 10-for-1 and changed its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.” (collectively, the “Merger”). As a result of the dilutive effects of the Merger, as of the date of this Amendment, Vifor (International) no longer beneficially owns more than five percent of the Common Stock.

Each of the Reporting Persons is filing this Amendment solely to report that it has ceased to be the beneficial owner of more than five percent of the Common Stock. This Amendment is the final amendment to the Schedule 13G and constitutes an exit filing for each Reporting Person.

Elicio Therapeutics, Inc. (the “Issuer”)

Elicio Therapeutics, Inc.

451 D Street, 5th Floor

Boston, Massachusetts

Vifor (International) Ltd.

Vifor Fresenius Medical Care Renal Pharma Ltd.

Vifor Pharma Ltd.

The foregoing persons are collectively referred to herein as the “Reporting Persons.” This Schedule 13G is being filed jointly by the Reporting Persons pursuant to an agreement of joint filing, a copy of which is attached hereto as Exhibit 99.1.

The address of the principal business office of each of the Reporting Persons is:

Rechenstrasse 37

CH-9014, St. Gallen

Switzerland

The place of organization of each of the Reporting Persons is Switzerland.

Common Stock, par value $0.001 per share

28657F103

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4 is hereby amended and restated in its entirety to read as follows:

As of July 6, 2023, the Reporting Persons’ respective beneficial ownership was as follows:

Amount beneficially owned: 199,564 shares

Percent of class: 0.02%

Sole voting power: 0 shares

Shared voting power: 199,564 shares

Sole dispositive power: 0 shares

Shared dispositive power: 199,564 shares

Amount beneficially owned: 0 shares

Percent of class: 0.0%

Sole voting power: 0 shares

Shared voting power: 0 shares

Sole dispositive power: 0 shares

Shared dispositive power: 0 shares

Amount beneficially owned: 0 shares

Percent of class: 0.0%

Sole voting power: 0 shares

Shared voting power: 0 shares

Sole dispositive power: 0 shares

Shared dispositive power: 0 shares

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

Not applicable.

Not applicable.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).